94 results
6-K
EX-99.1
SNY
Sanofi
15 Feb 24
Current report (foreign)
12:09pm
and makes Sanofi an ever more inclusive culture where everyday experiences matter for every employee worldwide. This wraps the program into a wider DE&I
6-K
EX-99.1
SNY
Sanofi
17 Jan 24
Brian Foard appointed Head of Specialty Care Global Business Unit, member of Sanofi Executive Committee
1:49pm
. He is clearly one of our leaders who has been actively contributing to the success of our Play to Win strategy while embracing our culture and values
6-K
EX-99.1
SNY
Sanofi
11 Oct 23
Sanofi announces agreement for potential first-in-class vaccine against extraintestinal pathogenic E. coli
6:05am
. 2020;395(10219):200-211. doi:10.1016/S0140-6736(19)32989-7
3 Rhee C, et al. Prevalence of Antibiotic-Resistant Pathogens in Culture-Proven Sepsis
6-K
EX-99.1
SNY
Sanofi
5 Sep 23
Sanofi announces changes to its Executive Committee
6:19am
a robust pipeline and sharpened its research focus, employing cutting-edge therapeutic platforms and creating a culture that responds to the urgent … skills and promoting a digital and data driven culture, Emmanuel and his teams will notably support Sanofi’s goal to become the first biopharma company
6-K
EX-99.2
SNY
Sanofi
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
, Finance, People & Culture, Legal Affairs, Ethics & Business Integrity, Information Solutions & Technology, Sanofi Business Services, etc.), which … now also has its own dedicated global support functions (including Finance, People & Culture, Legal Affairs, Ethics & Business Integrity, Information
6-K
EX-99.1
jcv0 yxxs
28 Jul 23
Condensed Half-year Consolidated Financial Statements
7:00am
6-K
EX-99.1
rsgy1jwhjs3 vb50qps
28 Oct 22
Continued strong growth in Q3 with key regulatory milestones achieved
11:16am
6-K
EX-99.2
vr5ilhwh7 rjlp
13 Jun 22
FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis
2:56pm
6-K
EX-99.1
4qc2bbkiopz
29 Apr 22
Current report (foreign)
12:38pm
6-K
EX-99.2
6gbkjaj31t
7 Apr 22
If approved, Dupixent would be the first medicine available in the U.S. indicated to treat eosinophilic esophagitis
3:13pm
6-K
EX-99.1
e2b36xu26yjd3ur
4 Apr 22
Distribution of Shares of Euroapi
11:21am
SC TO-T
EX-99
uay3v3 2rrr7igca
16 Aug 21
Third party tender offer statement
8:09am
6-K
EX-99.1
0h1sb
29 Jul 21
Sales growth accelerated - Full-year guidance raised
9:52am
6-K
EX-99.2
s948648j269bga8vp 8o
11 Feb 21
FDA approves Libtayo® (Cemiplimab-rwlc) as first immunotherapy indicated for patients with advanced basal cell carcinoma
3:17pm
6-K
EX-99.2
dujptb kxgqpmou
11 Dec 20
Sanofi and GSK announce a delay in their adjuvanted recombinant protein-based COVID-19 vaccine program to improve immune response in the elderly
3:25pm
6-K
EX-99.2
fork27j66
4 Nov 20
Sanofi offers to acquire Kiadis, a clinical-stage company developing cell-based immunotherapy products
3:27pm
SC TO-T
EX-99
b87fk65 d2jory4lqi
28 Aug 20
Third party tender offer statement
6:24am
6-K
EX-99.2
bvlublmbn qf2wl7a
29 Jul 20
2020 Half-year Financial Report
10:13am